

FAM83D and Malignant Tumors: A Brief Literature Review

Dekang Liu*, Xiaowei Guan*

Department of Human Anatomy and Histoembryology, Nanjing University of Chinese Medicine, Nanjing, China

Email address:

dekang@njucm.edu.cn (Dekang Liu), guanxw918@njucm.edu.cn (Xiaowei Guan)

*Corresponding author

To cite this article:

Dekang Liu, Xiaowei Guan. FAM83D and Malignant Tumors: A Brief Literature Review. *Biomedical Sciences*.

Vol. 8, No. 2, 2022, pp. 53-56. doi: 10.11648/j.bs.20220802.11

Received: April 1, 2022; Accepted: April 19, 2022; Published: April 26, 2022

Abstract: Background: FAM83D is a spindle related protein and plays critical roles in mid-plate formation during mitosis. Aberrant FAM83D expression was reported in multiple cancers. Besides, it was observed that FAM83D was capable of promoting the proliferation and migration of normal or cancer cells in several tissues. Objective: we are aiming to update the latest advancement in FAM83D findings, and make a comprehensive review of FAM83D, in order to provide new perspectives for the research of FAM83D in tumors. Methods: Here, we summarized the latest published literatures of FAM83D in recent five years and categorized the research of FAM83D into lung cancer, digestive system cancers and female reproductive cancers. Then, we discussed the relationship of FAM83D and diagnosis, development and prognosis of multiple cancers, as well as the relevant *in vitro* intracellular underlying mechanisms. Conclusions: Up to now, FAM83D has been investigated in 9 types of cancers and its expression patterns found to tightly related to OS or DFS. Besides, most *in vitro* studies showed that FAM83D positively regulated cancer cell proliferations and differentiations. Furthermore, researches screened out several downstream targets and intracellular pathways of FAM83D as well as upstream regulatory factors. Prospectively, the biochemistry features of FAM83D protein and its potential as a biomarker of cancer diagnosis or therapy require more independent and rigorous studies.

Keywords: FAM83D, Malignant Tumors, Tumor Biomarkers

1. Introduction

The FAM83D gene (Family with sequence similarity 83 member D), also named as CHICA or C20Orf129, is located on chromosome 20 [1]. FAM83D is relatively highly expressed during cell division, playing critical roles in mid-plate formation, sister chromatid separation and regulating the location of human Chromokinesin Kid to spindle during metaphases [2, 3]. Loss of FAM83D leads to dysfunctional spindle, failure of chromatid separation and consequential generation of aneuploidy. Furthermore, researchers have found that FAM83D was co-expressed with many known mitosis-related factors, including Aurora-A, Aurora-B, Plk-1, Plk-4, Cdc20, Cdk1, Nek2, Geminin and CENP protein family [4].

FAM83D belongs to FAM83 protein family (FAM83A-H), and its functions had long been elusive. The proteins in FAM83 family share a common domain of unknown function 1669 (DUF1669), which has weak homology to Phospholipase D [5]. Phospholipase D has been widely investigated in cell

proliferation and differentiation. Besides, database analysis showed that the expression level of FAM83D is negatively correlated with overall survival time in various types of cancers. Therefore, FAM83D is tightly related to cell division and may be correlated to cancer development. Here, we summarized the updated studies of FAM83D and discussed the possibility of FAM83D as biomarker or target in cancer diagnosis or therapy.

2. FAM83D and Lung Cancer

Up to date, three independent researches investigated the relationship of FAM83D expression and lung cancer development. First, through analysis of TCGA LUAD (lung adenocarcinoma) datasets, Shi R. *et al* found that compared to adjacent normal tissues, LUAD tissues showed significant upregulation of FAM83D expression and higher FAM83D expression related to higher DNA ploidy, corresponding well to previous *in vitro* study that loss of FAM83D leads to aneuploidy.

Besides, higher FAM83D expression was associated with shorter survival time. Finally, they performed *in vitro* assay and showed that FAM83D deficiency inhibited lung cancer cell lines A549 and H1299 proliferation and mobility [6].

Similarly, Yin C. *et al* found elevated FAM83D expression levels in high invasive non-small cell lung cancer (NSCLC) cell lines and in the distant metastasis of clinical samples. Interestingly, they illustrated that FAM83D promoted Epithelial-mesenchymal transition (EMT) in BEAS2B NSCLC cells but not in A549 and H1299 NSCLC cells, implying the discrepancy of FAM83D functions in different NSCLC cells. Additionally, they showed that FAM83D knockdown increases A549 and H1299 sensitivity to cisplatin *in vitro* and *in vivo* [7].

The latest article concerning FAM83D and lung cancer found that circFOXMI promote NSCLS development by sponging miR-614, which targets and promote FAM83D mRNA degradation. Consequently, they conclude that circFOXMI/miR-614/FAM83D axis may regulate cell proliferation and progression *in vitro* and *in vivo*, and lung cancer diagnosis and prognosis in clinic [8].

3. FAM83D and Digestive System Cancer

In total, four independent researches concerned the relationship of FAM83D and liver cancer. In clinical research, Liao W. *et al* found the positive correlation between FAM83D levels and alpha-fetoprotein levels (AFP), the clinical TNM stage, the presence of a portal vein tumor thrombus (PVTT), while negative correlation with disease free survival (DFS) and overall survival (OS) times no matter in the collected unadjusted group or in adjusted groups according to diagnostic indicators. Soon afterwards, Lin B. *et al* got the similar results by analyzing 150 clinic samples collected between 2006 and 2013 [9]. Additionally, they found better outcomes of patients with lower FAM83D after liver transplantation. More recently, another research investigated TCGA and GEO (33006, 45436, 84402) datasets, and demonstrated that compared to adjacent normal tissues, liver tumors exhibited higher FAM83D expression, and the higher FAM83D levels implied worse DFS and OS, higher recurrence rate and mortality and more advanced AJCC stages [10]. Their results indicated that FAM83D may serve as one independent marker for liver cancer progression diagnosis and survival times [11].

In vitro, Wang D. *et al* compared 30 liver cancer samples and corresponding adjacent normal tissues and found no differences in expression levels of FAM83A, FAM83B and FAM83C except for FAM83D. Besides, FAM83D levels were elevated in most liver cancer cell lines compared to normal liver cells. Moreover, FAM83D overexpression promoted proliferation and colony formation of Hep3B and Focus cell, while FAM83D knockdown inhibited that of SK-hep-1 and YY-8103 cells [12]. Lin B. *et al* reported FAM83D deficiency inhibited liver cancer stem cell growth and self-renewal *in vitro*, as well as tumor growth and tumor metastasis in mice [9].

As to pancreatic cancer, only one literature stated that FAM83D levels were up-regulated in pancreatic adenocarcinoma (PDAC) no matter in TCGA datasets or in collected clinical samples, and related to poor prognosis. Meanwhile, *in vitro* assay showed that FAM83D knockdown inhibited the growth and increased the gemcitabine sensitivity of PDAC cells BxPC3 and SW1990 [13].

Apart from digestive glands, FAM83D were also related to digestive tracts cancer development. Firstly, one group described higher FAM83D expression in esophageal squamous cell carcinoma (ESCC) tissues compared to adjacent normal tissues and tightly correlated to poorer clinical outcomes. Furthermore, FAM83D deficiency inhibited ESCC cells ECA109 and KYSE30 growth and increased their radiosensitivity *in vitro* and *in vivo* [14].

Secondly, two articles reported FAM83D expression is positively related to gastric cancer (GC) cells HS-746T, AGS and SGC-7901 growth, invasion and migration *in vitro* and *in vivo*. Besides, clinical samples and database analysis showed that FAM83D upregulation was observed in GC tissues and cell lines, and implicated poor prognosis of GC patients [15, 16].

Thirdly, two groups studied the role of FAM83D in colorectal cancer (CRC). One reported that FAM83D overexpression may promote HCT-15 and HT-29 cells proliferation and invasion *in vitro* [17]. The other study found that FAM83D levels are upregulated in clinical CRC samples and in CRC cells lines. Besides, FAM83D knockdown inhibited proliferation, colony formation, migration and invasion of HCT116 and SW480 CRC cells [18].

4. FAM83D and Female Reproductive System Cancer

In the year of 2019, two groups conducted the research about FAM83D and ovarian cancer. Both groups reported higher FAM83D levels in cancer tissues than normal tissues. Besides, patients with higher FAM83D levels exhibited shorter OS and DFS times and more advanced stages. One of the researches proposed that FAM83D may serve as an effective marker to distinguish low malignant potential tumor from invasive epithelial ovarian cancer. Like in other cancer types, FAM83D overexpression promoted growth, migration and invasion of ovarian cells *in vitro* [19, 20].

Similar to ovarian cancer, two groups' researches indicated that FAM83D is one of the genes up-regulated in endometrial cancer (EC), and higher expression was related to more advanced stages. It is worth to note that they showed that FAM83D levels in patients' blood would be an efficacious marker to predict the EC prognosis [21, 22].

Through database mining, four studies dig out the correlation between the expression of FAM83D and breast cancer. Zhai X. reported that FAM83D expression was negatively associated with the recurrence-free survival in triplet-negative breast cancer (TNBC) samples by analyzing GSE45827, GSE38959, GSE65194 datasets from GEO, while another research found FAM83D was associated with poor

relapse-free survival and OS of Luminal A type of breast cancers by analyzing dataset GDS2250 [23, 24]. Furthermore, RNA-seq data from GEO showed that FAM83D was one of the most highly regulated genes in TNBC [25]. Additional two studies reported that FAM83D was upregulated in breast cancer tissues and related to poor DFS regardless of breast cancer classification [26, 27]. Besides, *in vitro* assays showed that FAM83D overexpression promoted human mammary epithelial cell (HMEC and MCF10A) transformation, migration, invasion and anchorage-independent growth (AIG). One the other hand, knockdown of FAM83D in breast cancer MDA468 and BT549 cells dramatically inhibited cell growth and invasion [26, 28].

5. Conclusion

Above, we summarized the role of FAM83D in multiple

types of cancers with clinical data and laboratory *in vivo* and *in vitro* research data. To get one step further, we compressed all the key information in one table (Table 1). In the table, we involved the reported cellular pathways that FAM83D may regulate in cancer cells. Collectively, up to date, FAM83D has been reported critical roles to cell proliferation, migration and invasion in 9 types of cancers. Through high throughput screenings and validations, the downstream regulating factors/pathways of FAM83D have been identified (Table 1). Meanwhile, several studies indicated upstream factors that may regulate human FAM83D expression, including circFOXMI/miR-614 axis, miRNA-495 and promoter methylations [11, 17, 8]. However, we found no relationship between promoter methylation status and FAM83D expression levels in mice tissues during development, implying different regulating mechanisms in different physiological or pathological conditions [29].

Table 1. Summary of the role of FAM83D in cancers.

Cancer type	No. of literature reported	In vitro	In vivo	Targets
Lung	3	OE: promote growth, mobility KD: increase sensitivity to cisplatin	higher expression in cancer tissues and related to shorter OS.	influencing CCND1, CCNE1 expression
Liver	4	OE: promotes growth, colony formation. KD: inhibits growth, colony formation; inhibits stem cancer cells growth and self-renewal.	higher expression in cancer tissues; positive correlation with AFP, TNM stages, PVTT presence, recurrence rate; Negative with OS, PFS. KD inhibits metastasis in mice.	AKT/mTor; TGF- β , MAPK; CRAF, CD44, Hippo.
Pancreas	1	KD: inhibits the growth and increases the gemcitabine sensitivity	higher expression in cancer tissues; relates to poor prognosis	Wnt/ β -catenin
Esophagus	1	KD: inhibits the growth and EMT and increases the radio sensitivity	higher expression in cancer tissues; correlates to poorer clinical outcome; increases their radio sensitivity in mice	Akt/GSK-3 β /Snail
Stomach	2	positively relates to cells growth, invasion and migration	positively relates to tumor growth, invasion and migration	Wnt/ β -catenin
Colorecta	2	OE: promotes growth, invasion KD: inhibits the growth, colony formation, migration and invasion	higher expression in cancer tissues	PTEN/PI3K/AKT/mTor; FBXW7/Notch-1
Ovary	2	promotes growth, migration and invasion	higher expression in cancer tissues , relates to shorter OS and DFS times and more advanced stages	PI3K/AKT/mTOR
Endometria	2	-----	higher expression in cancer tissues, relates to more advanced stages	-----
Breast	4	OE: promotes migration, invasion transformation, KD: inhibits growth and invasion	higher expression and negatively associated with the recurrence-free survival in TNBC, poor relapse-free survival and OS in Luminal A type, poor DFS.	suppresses ERK phosphorylation; downregulates FBXW7 expression

OE: Over-expression; KD: Knockdown; OS: Overall survival; PFS: Progression-free survival; AFP: Alpha fetoprotein; PVTT: portal vein tumor thrombus.

As one proteins that tightly related to mitosis and had highly correlational expressions with CYCLINB1 [29], FAM83D was intensively investigated these years for its mechanisms in regulating cellular behavior. Prospectively, FAM83D may serve as one effective biomarker for cancer diagnosis or prognosis. Furthermore, given that FAM83D deficiency inhibited proliferations and migrations of in many types of cancer cells *in vitro* and *in vivo*, it has the potential to be one promising target for cancer therapy. Further studies of FAM83D may focus on three aspects: 1) how it regulates cell division or chromatin separation; 2) how it regulates downstream factors or cellular pathways and what is its biochemical features. 3) more retrospective and prospective clinical studies to validate its role

as biomarkers for cancer diagnosis and prognosis and its mutations landscape in cancer cases.

Conflict of Interest

The authors declare no statement of interest.

Acknowledgements

This research is supported by National Natural Science Foundation of China, Grant numbers: 31800682 and The Natural Science Foundation of the Jiangsu Higher Education Institutions of China, Grant numbers: 18KJB180019, 17KJB310008.

References

- [1] Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, *et al.* The DNA sequence and comparative analysis of human chromosome 20. *Nature*. 2001 Dec 20-27; 414 (6866): 865-71.
- [2] Sauer G, Korner R, Hanisch A, Ries A, Nigg EA, Sillje HH. Proteome analysis of the human mitotic spindle. *Mol Cell Proteomics*. 2005 Jan; 4 (1): 35-43.
- [3] Santamaria A, Nagel S, Sillje HHW, Nigg EA. The spindle protein CHICA mediates localization of the chromokinesin Kid to the mitotic spindle. *Curr Biol*. 2008 May 20; 18 (10): 723-29.
- [4] Varisli L. Meta-analysis of the expression of the mitosis-related gene Fam83D. *Oncol Lett*. 2012 Dec; 4 (6): 1335-40.
- [5] Bartel CA, Parameswaran N, Cipriano R, Jackson MW. FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance. *Oncotarget*. 2016 Aug 9; 7 (32): 52597-612.
- [6] Shi R, Sun J, Sun Q, Zhang Q, Xia W, Dong G, *et al.* Upregulation of FAM83D promotes malignant phenotypes of lung adenocarcinoma by regulating cell cycle. *Am J Cancer Res*. 2016; 6 (11): 2587-98.
- [7] Yin C, Lin X, Wang Y, Liu X, Xiao Y, Liu J, *et al.* FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer. *Cell Oncol (Dordr)*. 2020 Jun; 43 (3): 395-407.
- [8] Yu C, Cheng Z, Cui S, Mao X, Li B, Fu Y, *et al.* circFOXMI promotes proliferation of non-small cell lung carcinoma cells by acting as a ceRNA to upregulate FAM83D. *J Exp Clin Cancer Res*. 2020 Mar 30; 39 (1): 55.
- [9] Lin B, Chen T, Zhang Q, Lu X, Zheng Z, Ding J, *et al.* FAM83D associates with high tumor recurrence after liver transplantation involving expansion of CD44+ carcinoma stem cells. *Oncotarget*. 2016 Nov 22; 7 (47): 77495-507.
- [10] Liu X, Gao H, Zhang J, Xue D. FAM83D is associated with gender, AJCC stage, overall survival and disease-free survival in hepatocellular carcinoma. *Biosci Rep*. 2019 May 31; 39 (5).
- [11] Liao W, Liu W, Liu X, Yuan Q, Ou Y, Qi Y, *et al.* Upregulation of FAM83D affects the proliferation and invasion of hepatocellular carcinoma. *Oncotarget*. 2015 Sep 15; 6 (27): 24132-47.
- [12] Wang D, Han S, Peng R, Wang X, Yang XX, Yang RJ, *et al.* FAM83D activates the MEK/ERK signaling pathway and promotes cell proliferation in hepatocellular carcinoma. *Biochem Biophys Res Commun*. 2015 Mar 6; 458 (2): 313-20.
- [13] Hua YQ, Zhang K, Sheng J, Ning ZY, Li Y, Shi WD, *et al.* Fam83D promotes tumorigenesis and gemcitabine resistance of pancreatic adenocarcinoma through the Wnt/beta-catenin pathway. *Life Sci*. 2021 Feb 8: 119205.
- [14] Yang XX, Ma M, Sang MX, Zhang XY, Zou NY, Zhu SC. Knockdown of FAM83D Enhances Radiosensitivity in Coordination with Irradiation by Inhibiting EMT via the Akt/GSK-3beta/Snail Signaling Pathway in Human Esophageal Cancer Cells. *Onco Targets Ther*. 2020; 13: 4665-78.
- [15] Huang M, Ma X, Shi H, Hu L, Fan Z, Pang L, *et al.* FAM83D, a microtubule-associated protein, promotes tumor growth and progression of human gastric cancer. *Oncotarget*. 2017 Sep 26; 8 (43): 74479-93.
- [16] Wang F, Zhang S, Wei Y, Chen H, Jiao Z, Li Y. Upregulation of family with sequence similarity 83 member D expression enhances cell proliferation and motility via activation of Wnt/beta-catenin signaling and predicts poor prognosis in gastric cancer. *Cancer Manag Res*. 2019; 11: 6775-91.
- [17] Yan L, Yao J, Qiu J. miRNA-495 suppresses proliferation and migration of colorectal cancer cells by targeting FAM83D. *Biomed Pharmacother*. 2017 Dec; 96: 974-81.
- [18] Mu Y, Zou H, Chen B, Fan Y, Luo S. FAM83D knockdown regulates proliferation, migration and invasion of colorectal cancer through inhibiting FBXW7/Notch-1 signalling pathway. *Biomed Pharmacother*. 2017 Jun; 90: 548-54.
- [19] Zhang Q, Yu S, Lok SIS, Wong AST, Jiao Y, Lee LTO. FAM83D promotes ovarian cancer progression and its potential application in diagnosis of invasive ovarian cancer. *J Cell Mol Med*. 2019 Jul; 23 (7): 4569-81.
- [20] Zhu H, Diao S, Lim V, Hu L, Hu J. FAM83D inhibits autophagy and promotes proliferation and invasion of ovarian cancer cells via PI3K/AKT/mTOR pathway. *Acta Biochim Biophys Sin (Shanghai)*. 2019 May 23; 51 (5): 509-16.
- [21] Liu J, Wu Z, Sun R, Nie S, Meng H, Zhong Y, *et al.* Using mRNAsi to identify prognostic-related genes in endometrial carcinoma based on WGCNA. *Life Sci*. 2020 Oct 1; 258: 118231.
- [22] Uyar DS, Huang YW, Chesnik MA, Doan NB, Mirza SP. Comprehensive serum proteomic analysis in early endometrial cancer. *J Proteomics*. 2021 Mar 15; 234: 104099.
- [23] Perez-Pena J, Alcaraz-Sanabria A, Nieto-Jimenez C, Paez R, Corrales-Sanchez V, Serrano-Oviedo L, *et al.* Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors. *Oncotarget*. 2017 Mar 28; 8 (13): 21733-40.
- [24] Zhai X, Yang Z, Liu X, Dong Z, Zhou D. Identification of NUF2 and FAM83D as potential biomarkers in triple-negative breast cancer. *PeerJ*. 2020; 8: e9975.
- [25] Fei H, Chen S, Xu C. RNA-sequencing and microarray data mining revealing: the aberrantly expressed mRNAs were related with a poor outcome in the triple negative breast cancer patients. *Ann Transl Med*. 2020 Mar; 8 (6): 363.
- [26] Wang Z, Liu Y, Zhang P, Zhang W, Wang W, Curr K, *et al.* FAM83D promotes cell proliferation and motility by downregulating tumor suppressor gene FBXW7. *Oncotarget*. 2013 Dec; 4 (12): 2476-86.
- [27] Fu Y, Zhou QZ, Zhang XL, Wang ZZ, Wang P. Identification of Hub Genes Using Co-Expression Network Analysis in Breast Cancer as a Tool to Predict Different Stages. *Med Sci Monit*. 2019 Nov 23; 25: 8873-90.
- [28] Cipriano R, Miskimen KL, Bryson BL, Foy CR, Bartel CA, Jackson MW. Conserved oncogenic behavior of the FAM83 family regulates MAPK signaling in human cancer. *Mol Cancer Res*. 2014 Aug; 12 (8): 1156-65.
- [29] Li Q, Zhou K, Du D, Chen Y, Liu D, Guan X. Dynamic expression of FAM83D in peripheral organs at different ages in mice. *Gene Expr Patterns*. 2021 Sep; 41: 119199.